Presence of FLT3 Mutations Does Not Impair Stem Cell Mobilization and Feasibility of Autologous Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 9, 2006, Pages 981-986

  Ferrara, Felicetto ^a   Palmieri, Salvatore ^a   Pollio, Filiberto ^a   Lo Pardo, Catia ^a   Graziano, Daniela ^a   Celentano, Maria ^a   D'Amico, Maria Rosaria ^a   Vicari, Laura ^a   Izzo, Barbara ^b   Pane, Fabrizio ^b  

^a CARDARELLI HOSPITAL   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Acute myeloid leukemia; Autologous transplantation; FLT3 mutations; Stem cell mobilization

Indexed keywords

BUSULFAN; CD34 ANTIGEN; CYTARABINE; ETOPOSIDE; FETAL LIVER TYROSINE KINASE 3; FLT3 LIGAND; FLUDARABINE; IDARUBICIN; MITOXANTRONE; PROTEIN TYROSINE KINASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER REGRESSION; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEASIBILITY STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KARYOTYPE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; STEM CELL MOBILIZATION; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; DISEASE-FREE SURVIVAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; KARYOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; RETROSPECTIVE STUDIES;

EID: 33747367022     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.05.017     Document Type: Article

References (29)

1. Ferrara F. Unanswered questions in acute myeloid leukaemia. Lancet Oncol 5 (2004) 443-450
2. Tallman M.S., Gilliland D.G., and Rowe J.M. Drug therapy for acute myeloid leukemia. Blood 106 (2005) 1154-1163
3. Mrozek K., Heinonen K., and Bloomfield C.D. Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clin Haematol 14 (2001) 19-47
4. Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol 14 (2001) 497-529
5. Byrd J.C., Mrozek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia. results from Cancer and Leukemia Group B (CALGB 8461). Blood 100 (2002) 4325-4336
6. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia. a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96 (2000) 4075-4083
7. Kottaridis P.D., Gale R.E., Frew M.E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy. analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98 (2001) 1752-1759
8. Boissel N., Cayuela J.M., Preudhomme C., et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia 16 (2002) 1699-1704
9. Frohling S., Schlenk R.F., Breitruck J., et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics. a study of the AML Study Group Ulm. Blood 100 (2002) 4372-4380
10. Schnittger S., Schoch C., Dugas M., et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia. correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100 (2002) 59-66
11. Kottaridis P.D., Gale R.E., and Linch D. Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia. Leuk Lymphoma 44 (2003) 905-913
12. Choudhary C., Muller-Tidow C., Berdel W.E., and Serve H. Signal transduction of oncogenic Flt3. Int J Hematol 82 (2005) 93-99
13. Moore M.A. Converging pathways in leukemogenesis and stem cell self-renewal. Exp Hematol 33 (2005) 719-737
14. Naoe T., and Kiyoi H. Normal and oncogenic FLT3. Cell Mol Life Sci 61 (2004) 2932-2938
15. Drexler H.D., and Quentmeier H. FLT3. receptor and ligand. Growth Factors 22 (2004) 71-73
16. Sebastio L., Ferrara F., Vicari L., et al. Simultaneous occurrence of tetrasomy 21 and trisomy 8 in a patient with early blastic metamorphosis of chronic myeloproliferative disorder. Am J Hematol 50 (1995) 49-52
17. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Int Med 105 (1985) 620-625
18. Ferrara F., Morabito F., Martino B., et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol 18 (2000) 1295-1300
19. Ferrara F., D'Arco A.M., De Simone M., et al. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukaemia. Haematologica 90 (2005) 776-784
20. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
21. Ferrara F., Palmieri S., Annunziata M., et al. Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukaemia aged over 60 years undergoing autologous stem cell transplantation. Bone Marrow Transplant 34 (2004) 573-576
22. Ferrara F., Palmieri S., De Simone M., et al. High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. Br J Haematol 128 (2005) 234-241
23. Ferrara F., Palmieri S., and Mele G. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukaemia. Haematologica 89 (2004) 998-1008
24. Stirewalt D.L., and Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 3 (2003) 650-665
25. Yanada M., Matsuo K., Suzuki T., Kiyoi H., and Naoe T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia. a meta-analysis. Leukemia 19 (2005) 1345-1349
26. Kiyoi H., and Naoe T. FLT3 mutations in acute myeloid leukemia. Methods Mol Med 125 (2006) 189-197
27. Parcells B.W., Ikeda A.K., Simms-Waldrip T., Moore T.B., and Sakamoto M.K. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. Stem Cells 24 (2006) 1174-1184
28. Gale R.M., Hills R., Kottaridis P.D., et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML). an analysis of 1135 patients excluding acute promyelocytic leukemia, from the UK MRCAML10 and 12 trials. Blood 106 (2005) 3658-3665
29. Yoshimoto G., Nagafuji K., Miyamoto T., et al. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 36 (2005) 977-983